Canertinib (BioDeep_00000176973)

   

human metabolite blood metabolite


代谢物信息卡片


N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide

化学式: C24H25ClFN5O3 (485.163)
中文名称: 卡奈替尼
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
InChI: InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)

描述信息

C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor

同义名列表

4 个代谢物同义名

N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; Canertinib (CI-1033); Canertinib; CI-1033



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Bharat Bhushan, Swati Banerjee, Shirish Paranjpe, Kelly Koral, Wendy M Mars, John W Stoops, Anne Orr, William C Bowen, Joseph Locker, George K Michalopoulos. Pharmacologic Inhibition of Epidermal Growth Factor Receptor Suppresses Nonalcoholic Fatty Liver Disease in a Murine Fast-Food Diet Model. Hepatology (Baltimore, Md.). 2019 11; 70(5):1546-1563. doi: 10.1002/hep.30696. [PMID: 31063640]
  • Yiqiang OuYang, Wensheng Zou, Liang Peng, Zunhua Yang, Qidong Tang, Mengzi Chen, Shuang Jia, Hong Zhang, Zhou Lan, Pengwu Zheng, Wufu Zhu. Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors. European journal of medicinal chemistry. 2018 Jun; 154(?):29-43. doi: 10.1016/j.ejmech.2018.05.006. [PMID: 29775935]
  • Xiao Chang, Kang Lu, Ling Wang, Min Lv, Wenjun Fu. Astraglaus polysaccharide protects diabetic cardiomyopathy by activating NRG1/ErbB pathway. Bioscience trends. 2018 May; 12(2):149-156. doi: 10.5582/bst.2018.01027. [PMID: 29607874]
  • Wafaa Hassan, Kenny Chitcholtan, Peter Sykes, Ashley Garrill. Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells. Cancer letters. 2018 04; 420(?):168-181. doi: 10.1016/j.canlet.2018.02.013. [PMID: 29432847]
  • Aby Joiakim, Patricia A Mathieu, Catherine Shelp, Julie Boerner, John J Reiners. Epidermal Growth Factor Receptor Kinase Inhibitors Synergize with TCDD to Induce CYP1A1/1A2 in Human Breast Epithelial MCF10A Cells. Drug metabolism and disposition: the biological fate of chemicals. 2016 May; 44(5):665-71. doi: 10.1124/dmd.115.066274. [PMID: 26953171]
  • Laura Montermini, Brian Meehan, Delphine Garnier, Wan Jin Lee, Tae Hoon Lee, Abhijit Guha, Khalid Al-Nedawi, Janusz Rak. Inhibition of oncogenic epidermal growth factor receptor kinase triggers release of exosome-like extracellular vesicles and impacts their phosphoprotein and DNA content. The Journal of biological chemistry. 2015 Oct; 290(40):24534-46. doi: 10.1074/jbc.m115.679217. [PMID: 26272609]
  • Mukul Minocha, Varun Khurana, Bin Qin, Dhananjay Pal, Ashim K Mitra. Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib. International journal of pharmaceutics. 2012 Oct; 436(1-2):127-34. doi: 10.1016/j.ijpharm.2012.05.038. [PMID: 22688250]
  • Alan P Brown, Robert W Dunstan, Cynthia L Courtney, Kay A Criswell, Michael J Graziano. Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor. Toxicologic pathology. 2008 Apr; 36(3):410-9. doi: 10.1177/0192623308315827. [PMID: 18467688]
  • Ralph G Zinner, John Nemunaitis, Irene Eiseman, Hyung Ju C Shin, Stephen C Olson, James Christensen, Xin Huang, Peter F Lenehan, Nicholas J Donato, Dong M Shin. Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 May; 13(10):3006-14. doi: 10.1158/1078-0432.ccr-06-1958. [PMID: 17505003]
  • Alberto A Chiappori, Peter M Ellis, John Turner Hamm, Jacob David Bitran, Irene Eiseman, Jennifer Lovalvo, Diana Burnett, Stephen Olson, Peter Lenehan, Ralph Goldman Zinner. A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006 Nov; 1(9):1010-9. doi: NULL. [PMID: 17409987]
  • James G Christensen, Patrick W Vincent, Wayne D Klohs, David W Fry, Wilbur R Leopold, William L Elliott. Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor. Molecular cancer therapeutics. 2005 Jun; 4(6):938-47. doi: 10.1158/1535-7163.mct-04-0208. [PMID: 15956251]
  • John Nemunaitis, Irene Eiseman, Casey Cunningham, Neil Senzer, Adrienne Williams, Peter F Lenehan, Stephen C Olson, Paul Bycott, Michael Schlicht, Rebecca Zentgraff, Dong M Shin, Ralph G Zinner. Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 May; 11(10):3846-53. doi: 10.1158/1078-0432.ccr-04-1950. [PMID: 15897585]
  • Hailin Yang, Sung-Kwon Kim, Mikyung Kim, Pedro A Reche, Tiara J Morehead, Inger K Damon, Raymond M Welsh, Ellis L Reinherz. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. The Journal of clinical investigation. 2005 Feb; 115(2):379-87. doi: 10.1172/jci23220. [PMID: 15690085]
  • Emiliano Calvo, Anthony W Tolcher, Lisa A Hammond, Amita Patnaik, Johan S de Bono, Irene A Eiseman, Stephen C Olson, Peter F Lenehan, Heather McCreery, Patricia Lorusso, Eric K Rowinsky. Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Nov; 10(21):7112-20. doi: 10.1158/1078-0432.ccr-04-1187. [PMID: 15534081]
  • Patricia M Lorusso. Phase I studies of ZD1839 in patients with common solid tumors. Seminars in oncology. 2003 Feb; 30(1 Suppl 1):21-9. doi: 10.1053/sonc.2003.50029. [PMID: 12644981]